Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell therapy
Biotech
Janux's T-cell engager makes waves, again, with new data drop
Among patients with heavily pretreated prostate cancer, all 16 patients who received JANX007 achieved a 50% decline in prostate-specific antigens.
Zoey Becker
Dec 3, 2024 11:40am
BMS' CAR-T cracks down on lupus, achieving sustained responses
Nov 14, 2024 10:00am
Adaptimmune's cell therapy hits key goal in pivotal sarcoma test
Nov 13, 2024 2:57pm
Acepodia, Pfizer click together for chemistry-based cell therapy
Sep 3, 2024 5:00pm
Death drives Lyell to take 2-track approach to dose escalation
Jun 26, 2024 10:00am
Galapagos selects Adaptimmune cell therapy in $665M collab
May 31, 2024 9:40am
